Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients

Fred Hutchinson Cancer Center (FHCC)

Status and phase: Begins enrollment in 6 months; Phase 2

Conditions: Hematopoietic and Lymphatic System Neoplasm

Treatments: Biological: SARS-CoV-2 mRNA Vaccine ARCT-021; Biological: Tozinameran; Other: Survey Administration; Other: Electronic Health Record Review; Procedure: Biospecimen Collection

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT07390968

20962 (Other Identifier)

NCI-2026-00148 (Registry Identifier)

K24AI190345 (U.S. NIH Grant/Contract)

RG1125827

Details and patient eligibility

About

This phase IIb trial compares the effect of LUNAR-COV19 vaccine to Comirnaty vaccine in treating adult patients who have received a hematopoietic cell transplant (HCT). Guidelines recommend repeating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination of 3 messenger ribonucleic acid (mRNA) vaccines followed by a fourth booster 3-6 months after treatment. However, vaccination is less effective in HCT patients compared to healthy people due to impaired immune responses. LUNAR-COV19, a self-amplifying mRNA vaccine, may help the body's own immune system recognize the SARS-CoV-2 spike protein and fight the virus by using a special mRNA that copies itself for a stronger response. Vaccines made from mRNA with SARS-CoV-2, such as Comirnaty, may help the body build an effective immune response. This may provide active protection against SARS-CoV-2 infection. LUNAR-COV19 may be safe and tolerable and may generate a better and more durable immune response than the Comirnaty vaccine in adult patients who have received a HCT.

Full description

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive LUNAR-COV19 intramuscularly (IM) on days 1, 29 and 113 in the absence of medical conditions or unacceptable toxicity. Additionally, patients undergo nasal swab at screening and at time of suspected SARS-CoV-2 infection, as well as blood sample collection throughout the study.

ARM II: Patients receive SARS-CoV-2 Comirnaty IM on days 1, 29 and 113 in the absence of medical conditions or unacceptable toxicity. Additionally, patients undergo nasal swab at screening and at time of suspected SARS-CoV-2 infection, as well as blood sample collection throughout the study.

After completion of study treatment, patients are followed up at days 115, 120, 127, 141 and 281.

Enrollment: 56 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥ 18 years
• Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)
• Have received an allogeneic HCT within the prior 365 days
• Have no relapse or progression of underlying malignancy
• Have platelets ≥ 30,000/mm^3
• Not pregnant (confirmed with negative urine or serum pregnancy test, if applicable)
• Willingness to take study vaccine and complete necessary study procedures
• If of childbearing potential, must agree to use a highly effective method of birth control or abstain from heterosexual activity for the course of the study through at least 60 days after the last dose of the study vaccine

Exclusion criteria

• Current infection with SARS-CoV-2 or infection within the prior 28 day period
• Positive for SARS-CoV-2 by nasal swab polymerase chain reaction (PCR) at screening
• Currently receiving any approved, authorized, or investigational direct-acting antiviral drug against SARS-CoV-2
• Received any approved, authorized, or investigational monoclonal anti-SARS-CoV-2 antibody therapy within the prior 180 days before screening
• Received a SARS-CoV-2 vaccine after HCT or within 28 days prior to HCT
• Participation in any other concurrent clinical trial of an experimental treatment or prevention for SARS-CoV-2
• Receiving > 1 mg/kg/day corticosteroids within the prior 7 days
• Active infection that is not adequately controlled, as determined by the investigator
• Have received therapies that cause profound T-cell or B-cell depletion within 30 days of enrollment, or anticipated to receive such therapies within 3 months of enrollment
• Have received immunoglobulin replacement therapy (IGRT) within 30 days of enrollment, or anticipated to receive IGRT within 3 months of enrollment
• Have a history of suspected or documented myocarditis or pericarditis
• Any inability to take study vaccine or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study
• Individuals with a known history of severe hypersensitivity reactions, including anaphylaxis, or other significant adverse reactions to any vaccine or any vaccine excipient. Have any other condition that would, in the investigator's judgment, contraindicate participation in the clinical study due to safety concerns with clinical study procedures

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

56 participants in 2 patient groups

Arm I (LUNAR-COV19)

Experimental group

Description:

Patients receive LUNAR-COV19 IM on days 1, 29 and 113 in the absence of medical conditions or unacceptable toxicity. Additionally, patients undergo nasal swab at screening and at time of suspected SARS-CoV-2 infection, as well as blood sample collection throughout the study.

Treatment:

Other: Electronic Health Record Review

Procedure: Biospecimen Collection

Other: Survey Administration

Biological: SARS-CoV-2 mRNA Vaccine ARCT-021

Arm II (Comirnaty)

Experimental group

Description:

Patients receive SARS-CoV-2 Comirnaty IM on days 1, 29 and 113 in the absence of medical conditions or unacceptable toxicity. Additionally, patients undergo nasal swab at screening and at time of suspected SARS-CoV-2 infection, as well as blood sample collection throughout the study.

Treatment:

Other: Electronic Health Record Review

Procedure: Biospecimen Collection

Other: Survey Administration

Biological: Tozinameran